Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology and genetic data. This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.
Condition or disease
GliomaMolecular Sequence VariationGenetic Change
Diagnostic Test: Glioma groups based on molecular pathology or genetic variation
Precise classification based on molecular and genetic biomarkers/subgroups for gliomas is challenging. This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and genetic data (Whole exome sequencing, RNA sequencing, proteomics, etc). This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.
Overall Survival (OS) [ Time Frame: From enrollment to death of patients. Estimated about 5 years. ]
The length of time from enrollment until the time of death (OS, overall survival)
Biospecimen Retention: Samples With DNA
All participants have signed the informed consent. Fresh frozen tissues of participants are collected immediately after tumor resection and preserved in liquid nitrogen. Whole exome sequencing, RNA sequencing and proteomics are planed to be conducted.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
1 Year to 95 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects are all received tumor resection in the First Affiliated Hospital of Zhengzhou University.
Patients must have radiologically and histologically confirmed diagnosis of primary glioma
Life expectancy of greater than 3 months
Must receive tumor resection
Must have sufficient fresh frozen tissues for NGS
Signed informed consent
No sufficient amount of tumor tissues for detection of molecular pathology
Patients who are pregnant or breast feeding
Patients who are suffered from severe systematic malfunctions
Do not have sufficient fresh frozen tissues for NGS